NICE is unable to make a recommendation about the use in the NHS of ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia because no evidence submission was received from Novartis Pharmaceuticals UK. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance